Media stories about CVS Health (NYSE:CVS) have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than 6,000 news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CVS Health earned a news sentiment score of 1.00 on their scale. InfoTrie also assigned news articles about the pharmacy operator an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected CVS Health’s ranking:
- CVS Health posts mixed quarterly earnings results (msn.com)
- CVS Health (CVS) Q4 Earnings and Revenues Beat Estimates (finance.yahoo.com)
- Asian stocks change little ahead of more US-China talks (finance.yahoo.com)
- Edited Transcript of CVS earnings conference call or presentation 20-Feb-19 1:30pm GMT (finance.yahoo.com)
- CVS Health quarterly revenue rises 12.5% (foxbusiness.com)
Several research analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on CVS Health in a research note on Sunday, December 2nd. They issued an “overweight” rating and a $77.84 price target for the company. ValuEngine raised CVS Health from a “sell” rating to a “hold” rating in a research note on Tuesday, November 6th. UBS Group assumed coverage on CVS Health in a research note on Thursday, January 17th. They issued a “buy” rating and a $75.00 price target for the company. Bank of America reissued a “buy” rating and issued a $92.00 price target on shares of CVS Health in a research note on Thursday, January 3rd. Finally, Loop Capital set a $80.00 price target on CVS Health and gave the stock a “hold” rating in a research note on Friday, November 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $89.21.
Shares of CVS stock opened at $64.22 on Thursday. CVS Health has a fifty-two week low of $60.14 and a fifty-two week high of $82.15. The stock has a market cap of $71.19 billion, a P/E ratio of 10.88, a PEG ratio of 0.94 and a beta of 1.03. The company has a quick ratio of 1.94, a current ratio of 2.44 and a debt-to-equity ratio of 1.66.
CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 20th. The pharmacy operator reported $2.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.05 by $0.09. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The business had revenue of $54.42 billion during the quarter, compared to analysts’ expectations of $53.78 billion. During the same quarter last year, the business posted $1.92 earnings per share. The company’s quarterly revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts predict that CVS Health will post 6.98 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, February 4th. Investors of record on Friday, January 25th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, January 24th. This represents a $2.00 annualized dividend and a yield of 3.11%. CVS Health’s dividend payout ratio is currently 33.90%.
In related news, insider Larry J. Merlo sold 166,368 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $64.51, for a total value of $10,732,399.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David M. Denton sold 25,159 shares of the stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total value of $2,015,990.67. Following the completion of the transaction, the chief financial officer now owns 403 shares of the company’s stock, valued at approximately $32,292.39. The disclosure for this sale can be found here. Insiders have sold 435,534 shares of company stock valued at $29,245,258 in the last ninety days. Company insiders own 0.53% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Extremely Likely to Affect CVS Health (CVS) Share Price” was first published by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://macondaily.com/2019/02/21/somewhat-favorable-news-coverage-extremely-likely-to-affect-cvs-health-cvs-share-price.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Featured Article: Purposes and Functions of the Federal Reserve
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.